Tech Company Financing Transactions
ImmunoGenesis Funding Round
Private investors joined a $10.8 million funding round for ImmunoGenesis. This venture round closed on 12/4/2025.
Transaction Overview
Company Name
Announced On
12/4/2025
Transaction Type
Debt
Amount
$10,800,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 Holcombe Blvd J
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Website
Email Address
Overview
ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company re-envisioning treatment for immune-excluded tumors. Our deliberate drug development strategy is based in the pathology of these tumors. We are crafting sophisticated, science-driven immune therapies to target key mechanisms of immune resistance. Our approach could unlock the full potential of immunotherapy for the millions of patients who present with immune-excluded tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Barlow
Browse more venture capital transactions:
Prev: 12/4/2025: Eikona venture capital transaction
Next: 12/4/2025: Superbo venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs